相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- CRO acquisitions mid-trial create a 60-90 day high-friction period where TMF completeness can slip from 85-90% to below 70%, directly impacting FDA inspection readiness. - When sponsors are acquired after R&D downsizing, sites face 60-120 days of operational uncertainty with frozen budgets, unanswered invoices, and absent CRA contacts. - ICH E6(R3) and 21 CFR Part 312.52 require documented transfer-of-obligations agreements; sites must demand written confirmation of IND sponsor continuity during any transition. - Vertical integration of MSO and CRO functions under one parent entity raises GCP governance concerns that regulators are increasingly scrutinizing for monitoring independence.
- Tevogen Bio's PredicTcell™ model demonstrated significant improvements in beta testing, with recall accuracy increasing from 87% to 92% and precision improving from 40% to 48%. - The company has built a proprietary database containing over 655 million peptide sequences from approximately 24 million proteins, representing nearly 16 billion data points across multiple disease areas. - Tevogen.AI now operates three production AI agents that continuously evaluate 14 active peptide candidates and integrate wet lab results back into the system. - The platform aims to reduce drug development costs and time to market by improving target prediction before costly clinical trials begin.
- Tevogen Bio has commissioned Databricks to accelerate development of PredicTcell, its proprietary AI-driven target prediction model for precision immunotherapy. - The collaboration will enhance PredicTcell's capabilities in modeling immunologically active HLA+ peptide complexes and predicting T cell receptor engagement, based on Tevogen's ExacTcell platform. - This partnership represents the third pillar of Tevogen.AI's foundation, alongside Microsoft Research and Tevogen Bio's own clinical expertise, aimed at transforming precision medicine.
- Tevogen Bio has filed a USPTO patent for a unique T cell vaccine designed to target entire viral genomes, potentially overcoming mutation-based resistance seen with traditional vaccines. - The vaccine leverages Tevogen's proprietary Tevogen.AI-powered PredicTcell technology to identify peptides that stimulate T cell responses, differentiating it from conventional B cell-focused vaccines. - Initially prioritized for national security and military applications against biological threats, the company plans transparent development with potential for broader public health applications.
- Tevogen Bio has finalized an agreement with CD8 Technology Services to develop a turn-key facility supporting both pre-clinical research and GMP cell therapy production capabilities. - The strategic move aims to overcome capital barriers typically faced in building GMP capabilities at scale, while maintaining operational agility and controlling costs in developing off-the-shelf CD8+ T cell therapeutics. - This facility agreement follows Tevogen's earlier financing activities in 2024, including a $6 million Series C Preferred Stock investment and access to a $36 million line of credit, positioning the company for accelerated pipeline advancement.
- Tevogen Bio met with BARDA TechWatch team to showcase their ExacTcell technology, highlighting its potential as a scalable medical countermeasure against emerging viral threats. - The company's platform demonstrated positive safety results in proof-of-concept trials for TVGN 489, incorporating AI capabilities in its development process. - As a clinical-stage biotech firm, Tevogen Bio aims to develop off-the-shelf CD8+ cytotoxic T lymphocyte therapies for infectious diseases, cancers, and neurological disorders.
- Tevogen Bio's CEO, Dr. Saadi, reaffirmed his dedication to making therapeutics accessible to patients through the company's innovative business model. - The company's officers hold nearly 79% of outstanding shares, demonstrating confidence in Tevogen Bio's potential and long-term vision. - Tevogen Bio is advancing its ExacTcell™ technology to develop off-the-shelf T cell therapies for infectious diseases, cancers, and neurological disorders. - Tevogen Bio anticipates sharing updates on its pipeline, including a $1 billion oncology forecast for the launch year, indicating strong growth expectations.
- Tevogen Bio's TVGN 489, an allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes immunotherapy, demonstrates promising results in a Phase I clinical trial. - The trial showed symptom improvement and viral elimination in high-risk COVID-19 patients, including those immunocompromised, with no disease progression or Long COVID development. - TVGN 489 was well-tolerated across all tested doses, with no significant adverse events and did not interfere with endogenous anti-SARS-CoV-2 responses. - The study observed persistence of donor-derived CTLs through the 6-month follow-up, suggesting potential for sustained therapeutic effect.
